



Article

# Comparison of biological features of wild European rabbit mesenchymal stem cells derived from different tissues.

Alexandra Calle<sup>1</sup>, María Zamora-Ceballos<sup>2</sup>, Juan Bárcena<sup>2</sup>, Esther Blanco<sup>2</sup> and Miguel Ángel Ramírez<sup>1\*</sup>

<sup>1</sup> Departamento de Reproducción Animal, INIA, CSIC, 28040 Madrid, Spain

<sup>2</sup> Instituto Centro de Investigación en Sanidad Animal (CISA), INIA, CSIC, 28130 Madrid, Spain

\* Correspondence: Miguel Ángel Ramírez; [ramirez@inia.es](mailto:ramirez@inia.es)

**Abstract:** Although the European rabbit is an "endangered" species and a notorious biological model, the analysis and comparative characterization of new tissue sources of rabbit mesenchymal stem cells (rMSCs) has not been well studied. Here we report for the first time the isolation and characterization of rMSCs derived from an animal belonging to a natural rabbit population within the species native region. New rMSC lines were isolated from different tissues: oral mucosa (rOM-MSC), dermal skin (rDS-MSC), subcutaneous adipose tissue (rSCA-MSC), ovarian adipose tissue (rOA-MSC), oviduct (rO-MSC), and mammary gland (rMG-MSC). The six rMSC lines showed plastic adhesion with fibroblast-like morphology and were all shown to be positive for CD44 and CD29 expression (characteristic markers of MSCs), and negative for CD34 or CD45 expression. In terms of pluripotency features, all rMSC lines expressed NANOG, OCT4, and SOX2. Furthermore, all rMSC lines cultured under osteogenic, chondrogenic, and adipogenic conditions showed differentiation capacity. In conclusion, this study describes the isolation and characterization of new rabbit cell lines from different tissue origins, with a clear mesenchymal pattern. We show that rMSC do not exhibit differences in terms of morphological features, expression of the cell surface, and intracellular markers of pluripotency and *in vitro* differentiation capacities, attributable to their tissue of origin.

**Citation:** Lastname, F.; Lastname, F.; Lastname, F. Title. *Int. J. Mol. Sci.* **2021**, *22*, x. <https://doi.org/10.3390/xxxxx>

Academic Editor: Firstname Lastname

Received: date

Accepted: date

Published: date

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2021 by the authors.

Submitted for possible open access

publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

The European rabbit (*Oryctolagus cuniculus*) originated in the Iberian Peninsula. The species expanded through anthropogenic dispersal to Europe, Australia, New Zealand, the Americas, and North Africa [1]. A single origin of domestication led to lower levels of genetic diversity within domestic rabbits than those found in wild populations [2]. Thus, natural populations within the European rabbit native region, the Iberian Peninsula, are considered a reservoir of genetic diversity [3]. Over the last 70 years, the European rabbit populations, both in its native and non-native ranges, have suffered declining population trends as reflected in the successive declaration statuses by IUCN: 1996 - Lower Risk / least concern (LR / LC); 2008 - Near Threatened (NT) and finally 2018 - Endangered (<https://www.iucnredlist.org/species/41291/170619657>). The emergence of two viral diseases: myxomatosis and rabbit hemorrhagic disease (RHD) was the primary cause of the decline [4–7]. In this context, the European rabbit provides a suitable system to study host-viral pathogen interactions, coevolution, and ecological effects [8–11].

The European rabbit has been extensively studied as a laboratory model for human diseases in both biomedical and fundamental research [12]. After mice (60.9%) and rats (13.9%), the laboratory rabbit is the third most used mammal model in animal experimentation (3.12%) within the EU. Furthermore, the highest increase in comparison to the previous report in 2008 is noted for fish and rabbits (EU report 2013: <https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52013DC0859>). However, our current knowledge of important aspects such as rabbit immunogenetics or the characterization of mesenchymal stem cells (MSCs) lags behind that of other relevant model species, like the mouse.

MSCs are widely utilized in therapy because of their immunomodulatory properties [13], but their potential application in infectious viral diseases is less explored. MSCs are susceptible to infection by a wide variety of RNA and DNA viruses both *in vitro* and *in vivo* [14–17]. Despite their permissiveness to some viruses' entry, some evidence has also emerged that MSCs can mitigate viral infection via the upregulation of antiviral mechanisms. MSC-released miRNAs have been reported to inhibit hepatitis C virus replication [18]. MSCs can interact with and influence both the innate and adaptive immune cells, potentially altering the outcome of the response to a viral infection. While there is already information in the literature regarding the use of MSCs and/or their secretome as a therapy in several animal models of viral diseases, their applications in rabbits have still not been assessed [19].

MSCs have been found in some rabbit tissues (adipose, gingival, bone marrow, Wharton's jelly, amniotic fluid) exhibiting stem cell characteristics such as plastic adherence, multilineage differentiation capacity, MSC marker expression, and pluripotent gene expression [20–23]. Postnatal organs and tissues are good MSC sources; however, each source of MSCs has a different degree of differentiation potential and expression of a different set of stem cell-related markers, as well as other important characteristics such as high proliferation, immunomodulation, and allo- and xeno-transplantation ability.

Rabbit MSCs (rMSC) have been widely used as preclinical models for orthopedic, specifically bone, articular cartilage, ligament reconstruction, and spinal fusion, as well as cardiovascular regenerative medicine strategies [24–27]. Although rMSCs are being investigated in these models, they have not been fully characterized in terms of immunophenotype and differentiation potential, and many tissues have not yet been explored as a source of MSC in the rabbit. Moreover, all the previous rMSC reported in the literature had been obtained from domestic New Zealand White (NZW) line rabbits. Here we report for the first time the isolation and characterization of rMSC obtained from a female

specimen belonging to a wild rabbit population of the species native range, the Iberian Peninsula.


The main goal of the present work was to perform the characterization of rMSC lines isolated from different tissues, in terms of morphological features, expression of mesenchymal and pluripotency-related markers, and *in vitro* chondrogenic, osteogenic and adipogenic differentiation capacities.

## 2. Results

### 2.1. Morphological features of different rMSC

As shown in Figure 1, we could successfully isolate rMSC from ovarian adipose tissue, subcutaneous adipose tissue, dermal skin, oral mucosa, oviduct, and mammary gland of an adult female wild rabbit.


In primary culture, rMSCs of all six sources adhered to the plastic surface of culture dishes, exhibiting a mixture of round, spindle, or elongated shape morphologies (Figure 1—upper panels). However, after the first cell passage, cells formed a homogeneous population of fibroblast-like adherent cells (Figure 1—lower panels).



**Figure 1.** Phase-contrast images of different rabbit rMSC lines at 6 days of culture of Passage 0 (upper panels;  $\times 100$  magnification) and Passage 17 (lower panels;  $\times 200$  magnification). Bars = 50  $\mu$ m.

### 2.2. Immunophenotypic characterization by flow cytometry

For further characterization of all six types of rMSCs, some characteristic cell surface markers were assessed by flow cytometry (Figure 2). Cell surface CD44, a characteristic marker of rMSCs, was expressed at detectable levels in all cell lines. In none of the rMSC lines, expression of hematopoietic lineage markers like CD34 and CD45 was detected.



99


**Figure 2.** Analysis by flow cytometry of the expression levels of cell surface markers CD34, CD44, and CD45 in rOA-MSC, rSCA-MSC, rDS-MSC, rOM-MSC, rO-MSC, rMG-MSC, and RK13 rabbit kidney epithelial cells. Plots depict the log of fluorescence intensity for each sample and bar charts the mean fluorescence intensity related to the negative control sample.

100  
101  
102  
103

### 2.3. Gene expression of surface and pluripotency markers detected by RT-PCR

104  
105  
106  
107  
108  
109

RT-PCR analyses confirmed the expression in all rMSCs lines of those CD surface markers that are characteristic of MSCs (CD29 and CD44) (Figure 3). In addition, CD34 and CD45, hematopoietic lineage markers, could not be detected at the mRNA level in the tested samples. Pluripotent markers OCT4, SOX2, and NANOG were detected by RT-PCR to be expressed in all rMSC lines.



110  
111  
112  
113  
114


**Figure 3.** RT-PCR analysis of surface and pluripotency marker gene expression in the different rMSC. A panel of surface markers including CD29, CD34, CD44, and CD45 was used for the identification of rMSC. Pluripotency genes expression (NANOG, OCT4, and SOX2) was detected in the different rMSC.

115  
116  
117  
118  
119  
120  
121  
122  
123  
124

### 2.4. In vitro differentiation of rMSCs

As shown in Figure 4, all rMSC lines cultured under chondrogenic conditions showed the presence of acidic proteoglycan synthesized by chondrocytes that were demonstrated at the monolayer of cells by Alcian blue staining, which appeared in most cases as stained nodules typical from cartilaginous tissue. Cells cultured under osteogenic conditions presented remarkable calcium deposits, indicating a high osteogenic differentiation potential of these lines. All rMSC lines obtained were also able to differentiate to adipocytes when cultured under adipogenic conditions, presenting the formation of cytoplasmic lipid droplets visualized after the Oil red O solution stain.

115  
116  
117  
118  
119  
120  
121  
122  
123  
124



**Figure 4.** *In vitro* differentiation of rMSC to different lineages. Images show Alcian blue staining of acidic proteoglycan in cells cultured in chondrogenic differentiation medium (top panel); Alizarin Red S staining of calcium deposits in cells cultured in osteogenic differentiation medium (middle panels); and Oil red O staining of lipid droplets in cells cultured in adipogenic differentiation medium (bottom panels). Bright-field images were acquired with 200 $\times$  magnification (bars = 50  $\mu$ m) for top and middle panels and with 400 $\times$  magnification (bars = 100  $\mu$ m) for bottom panels.

125  
126  
127  
128  
129  
130

### 3. Discussion

131

Our findings revealed that rabbit MSCs could be isolated and expanded *in vitro* from visceral adipose depots, subcutaneous fat, dermal skin, oral mucosa, oviduct, and mammary gland tissues of an adult female wild rabbit. Our results also demonstrate that rOA-MSCs, rSCA-MSCs, rDS-MSCs, rOM-MSC, rO-MSC, and rMG-MSCs shared similar characteristics in terms of morphology, expression of mesenchymal and pluripotency-related markers, and differentiation ability into chondrocytes, osteocytes, and adipocytes. Passaged cells had a more homogeneous morphology and formed colonies as the culture progressed, compared to primary cultures. As we have shown in previous studies in porcine and bovine species, these morphological observations indicate that the isolated cells may contain both mature and progenitor populations [28–30].

132  
133  
134  
135  
136  
137  
138  
139  
140  
141

Regarding cell surface markers characteristic of rMSC, contradictory results have been described in rabbits, as summarized by Zomer et al. [31]. Considering this, we have selected a panel of antibodies that have shown high sensitivity and repeatability and confirmed these results through RT-PCR assessment of expression at the mRNA level. Our data demonstrate that all rMSCs isolated were negative for CD34 and CD45 but positive for CD44, CD29, NANOG, OCT4, and SOX2, coinciding with the results reported in the literature for rMSCs isolated from different tissues: adipose [20], gingival [21], amniotic fluid [23] and bone marrow [25, 32].

142  
143  
144  
145  
146  
147  
148  
149

The basic *in vitro* trilineage differentiation capacity of rMSC, that is adipocytes, osteocytes, and chondrocytes have been reported in the literature only for adipose [31] and for bone marrow rMSC [25, 26, 33]. Our results show that all isolated rMSC lines, regardless of their tissue of origin, were able to differentiate to the three mesodermal lineages, with lipid droplet accumulation, calcium deposits, or presence of proteoglycan in response to *in vitro* adipogenic, osteogenic, or chondrogenic stimuli, respectively.

150  
151  
152  
153  
154  
155

The gene expression profile of adipose MSC from subcutaneous fat in Zucker rats was found to be distinct from the gene expression profiles of the other four visceral designated depots (epicardial, epididymal, mesenteric, and retroperitoneal), which clustered together but were not identical [34]. Also, differences between adipose-MSC from mesenteric and omental depots have been documented [35]. These findings show that individual visceral "subdepots" should not be considered interchangeable. Moreover, increased visceral (central) fat is more pathological, resulting in insulin resistance and chronic inflammation, whereas subcutaneous (peripheral) fat is more beneficial in systemic metabolism [36]. These differences are cell-intrinsic and persist in culture [35, 37], revealing the mechanisms underlying the pathophysiological differences between adipose depots. Individual adipose depots, which function as separate "mini-organs," are formed and maintained by distinct A-MSC populations, with consistent differences in adipogenic potential and function later in life [38, 39]. We have however not observed major differences between rMSCs isolated from subcutaneous adipose tissue or ovarian adipose depot, although it would be interesting to make a more in-depth characterization.

156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171

Rabbit embryo and fetoplacental development are similar to human development, making the rabbit an excellent model for studying embryo-maternal communication, the effects of maternal metabolic disorders on offspring development and long-term health [40], and the development of *in vitro* models of pathogen infection during pregnancy. In 2009 Jazedje *et al.* showed for the first time that human fallopian tubes are a rich additional source of MSCs and these cells were designated as human tube MSCs (htMSCs) [41]. The presence of mesenchymal cell populations in this part of the female reproductive system has only been documented in humans until now [42–45]. Our rO-MSC will allow the development of both physiological and pathological *in vitro* models.

172  
173  
174  
175  
176  
177  
178  
179  
180

Due to the remarkable cyclical changes in proliferation, lactation, and involution that occur in the breast tissue throughout life and pregnancy, the field of mammary gland physiology has been historically interested in stem cell biology. Shackleton *et al.* demonstrated that a single cell lacking hematopoietic and endothelial antigens, and expressing high levels of CD29 could generate an entire mammary gland [46]. Following this description, in rMG-MSC we found no expression of the hematopoietic lineage markers CD34 and CD45, while they expressed CD29 and CD45 as well as pluripotency markers (NANOG, OCT4, and SOX2). Mammary gland stem cells have subsequently been shown to play key roles in both regeneration of the mammary gland and the development of mammary gland tumors. CD44 has been used as a marker of cancer-initiating cells in various cancers, including prostate, pancreas, and colon [47, 48]. Considering the above, rMG-MSC is a promising *in vitro* model for the study of both breast physiology and breast cancer, since it expressed CD44. Until now the presence of MSCs in the mammary gland has only been studied in mice [49–52].

181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194

The fact that rabbit hemorrhagic disease virus (RHDV), a relevant member of the Calicivirusidae family, cannot be propagated *in vitro*, has greatly hampered the progress of investigations into its mechanisms of pathogenesis, translation, and replication. In this regard, the isolation of new rMSC lines from target tissues for the main viral pathogens of the species (myxoma virus and RHDV) will allow an in-depth analysis of both their susceptibility to viral infection and their possible role in the regulation of host antiviral response.

195  
196  
197  
198  
199  
200  
201

## 4. Materials and Methods

202

### 4.1. Isolation and culture of rMSCs

203

Different tissue samples were obtained postmortem from an adult female wild rabbit (*Oryctolagus cuniculus*). 204  
205

For the isolation of primary mesenchymal cultures from oral mucosa (rOM-MSC), dermal skin tissue (rDS-MSC), subcutaneous adipose tissue (rSCA-MSC), ovarian adipose tissue (rOA-MSC), oviduct (rO-MSC), and mammary gland (rMG-MSC), the procedures are detailed in Calle et al. [28]. Briefly, the collected samples were minced before the tissues were incubated in a collagenase type I solution. Thereafter, a volume of culture medium was added to block the action of collagenase. The resulting pellets were resuspended in culture medium and plated in a 100-mm<sup>2</sup> tissue culture dish (Jet-Biofil, Guangzhou, China) and incubated in an atmosphere of humidified air and 5% CO<sub>2</sub> at 37 °C. The culture medium was changed every 48–72 h. Isolated colonies of putative rMSCs were apparent after 5–6 days in culture and were maintained in growth medium until ~75% confluence. The cells were then treated with 0.05% trypsin–EDTA (T/E) and further cultured for subsequent passage in 100-mm<sup>2</sup> dishes at 50,000 cells/cm<sup>2</sup>. 206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217

#### 4.2. Immunocytochemical analysis by flow cytometry

Cell cultures at 80–90% confluence were detached and fixed with 4% paraformaldehyde for 10 min. Stainings were performed as detailed in Calle et al. [28], employing anti-CD44 (clone W4/86, Bio-Rad); anti-CD34 (Mouse monoclonal, Invitrogen), and anti-CD45 (clone L12/201, Bio-Rad). Appropriated secondary staining using F(ab')2-Goat anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, APC (A10539) from Life Technologies. Negative control samples corresponded to samples in which the primary antibody was omitted. Samples were analyzed in a FACSCalibur (BD Biosciences) using Flow-JoX Software® version 10.0.7r2. 218  
219  
220  
221  
222  
223  
224  
225  
226

#### 4.3. RT-PCR analysis of characteristic mesenchymal mRNA expression in rMSC

Total RNA was extracted from 2.5 · 10<sup>6</sup> cells by RNeasy Mini kit (Qiagen), according to the manufacturer's instructions. The RNA starting template was analyzed for integrity and quantity by Nanodrop test, and 600 ng were used in the RT-PCR reaction. cDNA was synthesized and amplified using OneStep RT-PCR Kit (Qiagen), according to the manufacturer's instructions, and using the following gene-specific primers: Rabbit CD29, forward (AGAATGTCACCAACCGTAGCA), reverse (CACAAAGGAGCCAAACCCA); rabbit CD44, forward (TCATCCTGG- CATCCCTCTTG), reverse (CCGTTGCCATT-GTTGATCAC); rabbit CD45, forward (TACTCTGCCTCCCGTTG), reverse (GCTGAG-TGTCTGGTGTGTC); rabbit CD34, forward (TTTCCTCATGAACCGTCGCA), reverse (CGTGTGTTGCTTGCAGGAATGG); NANOG, forward (GCCAGTCGTGGAGTAACCAT), reverse (CTGCATGGAGGACTGTAGCA); OCT4, forward (GAGGAGTCCCAG-GACATGAA), reverse (GTGGTTGGCTGAACACCTT); SOX2, forward (CAGCTCG-CAGACCTACATGA), reverse (TGGAGTGGAGGAAGAGGTA) [23]. PCR products were separated on a 1.5% agarose gel (MB Agarose, Bio-Rad) stained with GelRed® Nucleic Acid Gel Stain (Biotium, #41002). 227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242

#### 4.4. In vitro differentiation potential assay

For adipogenic, osteogenic, and chondrogenic differentiation, cells were cultured according to the manufacturer's instructions of the StemPro® adipogenesis, osteogenesis, or chondrogenesis differentiation kits, respectively (Thermo Fisher Scientific, Meridian Road Rockford, IL) and analyzed as detailed in Calle et al. [28]. 243  
244  
245  
246  
247

## 5. Conclusions

248

In summary, this study describes the isolation and characterization for the first time of cell lines from different tissue origins with a clear mesenchymal pattern, derived from a natural rabbit population within the species native region. We show that rMSCs do not present differences in terms of morphological features, expression of the cell surface, and intracellular markers of pluripotency and *in vitro* chondrogenic, osteogenic and adipogenic differentiation capacities attributable to their tissue of origin.

**Author Contributions:** Conceptualization, M.Á.R.; methodology, M.Á.R., E.B. and A.C.; software, M.Á.R. and A.C.; validation, M.Á.R., E.B., J.B., and A.C.; formal analysis, M.Á.R. E.B. and A.C.; investigation, M.Á.R., E.B., J.B., M.Z. and A.C.; resources, M.Á.R., E.B., J.B., M.Z. and A.C.; data curation, M.Á.R. E.B. and A.C.; writing—original draft preparation, M.Á.R.; writing—review and editing, M.Á.R., E.B., J.B., M.Z. and A.C.; visualization, M.Á.R., and A.C.; supervision, M.Á.R.; project administration M.Á.R., E.B. and J.B.; funding acquisition, M.Á.R., E.B. and J.B. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was supported by grants from Spanish Ministerio de Ciencia e Innovación (PID2019-107145RB-I00), Spanish Ministerio para la Transición Ecológica y el Reto Demográfico, through Fundación Biodiversidad (PRCV00820) and European Union's Horizon 2020 Research and Innovation Programme VetBioNet (grant agreement No. 731014).

**Acknowledgments:** The authors are grateful to Dra María Yáñez-Mó (Dpto. de Biología Molecular, UAM, Madrid, Spain) for critical reading of the manuscript.

The authors thank Marta Díaz-de Frutos for her experimental assistance during her stay at CISA, INIA.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Ferreira, P., Catarina. European rabbit research in the Iberian Peninsula: State of the art and future perspectives. *European Journal of Wildlife Research.* **2012**, 58, 885-895. <https://doi.org/10.1007/s10344-012-0664-9>
2. Carneiro, M.; Afonso, S.; Geraldes, A.; Garreau, H.; Bolet, G.; Boucher, S.; Tirczales, A.; Queney, G.; Nachman, M.W., Ferrand, N. The genetic structure of domestic rabbits. *Mol Biol Evol.* **2011**, 28, 1801-1816. <https://doi.org/10.1093/molbev/msr003>
3. Alves, J.M. et al. Levels and Patterns of Genetic Diversity and Population Structure in Domestic Rabbits. *PLoS One.* **2015**, 10, e0144687. <https://doi.org/10.1371/journal.pone.0144687>
4. Abrantes, J.; van der Loo, W.; Le Pendu, J.; Esteves, P.J. Rabbit haemorrhagic disease (RHD) and rabbit haemorrhagic disease virus (RHDV): a review. *Vet Res.* **2012**, 43, 12. <https://doi.org/10.1186/1297-9716-43-12>
5. Bertagnoli, S., Marchandea, S. Myxomatosis. *Rev Sci Tech.* **2015**, 34, 549-56, 539. <https://pubmed.ncbi.nlm.nih.gov/26601455>
6. Rouco, C. et al. Epidemiology of RHDV2 (Lagovirus europaeus/GI.2) in free-living wild European rabbits in Portugal. *Transbound Emerg Dis.* **2018**, 65, e373-e382. <https://doi.org/10.1111/tbed.12767>
7. Villafuerte, R.; Castro, F.; Ramírez, E.; Cotilla, I.; Parra, F.; Delibes-Mateos, M.; Recuerda, P., Rouco, C. Large-scale assessment of myxomatosis prevalence in European wild rabbits (*Oryctolagus cuniculus*) 60years after first outbreak in Spain. *Res Vet Sci.* **2017**, 114, 281-286. <https://doi.org/10.1016/j.rvsc.2017.05.014>
8. Effler, P. Australia's War against Rabbits: The Story of Rabbit Haemorrhagic Disease. *Emerging Infectious Disease journal.* **2015**, 21, 735. <https://doi.org/10.3201/eid2104.142009>
9. Wilkinson, L. Frank Fenner and Bernardino Fantini, Biological control of vertebrate pests: the history of myxomatosis, an experiment in evolution, Wallingford, CABI Publishing, 1999, pp. xii, 339, illus., £60.00 (0-85199-323-0). *Medical History.* **2001**, 45. <https://doi.org/10.1017/S0025727300067594>
10. Kerr, P.J.; Hall, R.N., Strive, T. Viruses for Landscape-Scale Therapy: Biological Control of Rabbits in Australia. *Methods Mol Biol.* **2021**, 2225, 1-23. [https://doi.org/10.1007/978-1-0716-1012-1\\_1](https://doi.org/10.1007/978-1-0716-1012-1_1)
11. Monterroso, P. et al. Disease-mediated bottom-up regulation: An emergent virus affects a keystone prey, and alters the dynamics of trophic webs. *Sci Rep.* **2016**, 6, 36072. <https://doi.org/10.1038/srep36072>
12. Burkholder, T.; Linton, G.; Hoyt, R., Young, R. The Rabbit as an Experimental Model. *The Laboratory Rabbit, Guinea Pig, Hamster, and Other Rodents.* **2012**, 529-560. <https://doi.org/10.1016/B978-0-12-380920-9.00018-3>
13. Cagliani, J.; Grande, D.; Molmenti, E.P.; Miller, E.J., Rilo, H.L.R. Immunomodulation by Mesenchymal Stromal Cells and Their Clinical Applications. *J Stem Cell Regen Biol.* **2017**, 3, 1-26. <https://doi.org/10.15436/2471-0598.17.022>
14. Avanzi, S. et al. Susceptibility of human placenta derived mesenchymal stromal/stem cells to human herpesviruses infection. *PLoS One.* **2013**, 8, e71412. <https://doi.org/10.1371/journal.pone.0071412>

15. Arzi, B.; Kol, A.; Murphy, B.; Walker, N.J.; Wood, J.A.; Clark, K.; Verstraete, F.J.; Borjesson, D.L. Feline foamy virus adversely affects feline mesenchymal stem cell culture and expansion: implications for animal model development. *Stem Cells Dev.* **2015**, *24*, 814–823. <https://doi.org/10.1089/scd.2014.0317> 302  
303  
304

16. Cheung, M.B.; Sampayo-Escobar, V.; Green, R.; Moore, M.L.; Mohapatra, S.; Mohapatra, S.S. Respiratory Syncytial Virus-Infected Mesenchymal Stem Cells Regulate Immunity via Interferon Beta and Indoleamine-2,3-Dioxygenase. *PLoS One.* **2016**, *11*, e0163709. <https://doi.org/10.1371/journal.pone.0163709> 305  
306  
307

17. Claessen, C.; Favoreel, H.; Ma, G.; Osterrieder, N.; De Schauwer, C.; Piepers, S.; Van de Walle, G.R. Equid herpesvirus 1 (EHV1) infection of equine mesenchymal stem cells induces a pUL56-dependent downregulation of select cell surface markers. *Vet Microbiol.* **2015**, *176*, 32–39. <https://doi.org/10.1016/j.vetmic.2014.12.013> 308  
309  
310

18. Qian, X.; Xu, C.; Fang, S.; Zhao, P.; Wang, Y.; Liu, H.; Yuan, W.; Qi, Z. Exosomal MicroRNAs Derived From Umbilical Mesenchymal Stem Cells Inhibit Hepatitis C Virus Infection. *Stem Cells Transl Med.* **2016**, *5*, 1190–1203. <https://doi.org/10.5966/sctm.2015-0348> 311  
312  
313

19. Taechangam, N.; Kol, A.; Arzi, B.; Borjesson, D.L. Multipotent Stromal Cells and Viral Interaction: Current Implications for Therapy. *Stem Cell Rev Rep.* **2021**. <https://doi.org/10.1007/s12015-021-10224-9> 314  
315

20. Tirpáková, M.; Vašíček, J.; Svoradová, A.; Baláži, A.; Tomka, M.; Bauer, M.; Makarevich, A.; Chrenek, P. Phenotypical Characterization and Neurogenic Differentiation of Rabbit Adipose Tissue-Derived Mesenchymal Stem Cells. *Genes (Basel).* **2021**, *12*. <https://doi.org/10.3390/genes12030431> 316  
317  
318

21. Nugraha, A.P.; Rantam, F.A.; Narmada, I.B.; Ernawati, D.S.; Ihsan, I.S. Gingival-Derived Mesenchymal Stem Cell from Rabbit (*Oryctolagus cuniculus*): Isolation, Culture, and Characterization. *Eur J Dent.* **2021**, *15*, 332–339. <https://doi.org/10.1055/s-0040-1719213> 319  
320  
321

22. Li, L.; Dong, J.; He, Y.; Mao, W.; Tang, H.; Dong, Y.; Lyu, F. Comparative analysis of mesenchymal stromal cells derived from rabbit bone marrow and Wharton's jelly for adipose tissue engineering. *Connect Tissue Res.* **2020**, *61*, 537–545. <https://doi.org/10.1080/03008207.2019.1631297> 322  
323  
324

23. Kovac, M.; Vasicek, J.; Kulikova, B.; Bauer, M.; Curlej, J.; Balazi, A.; Chrenek, P. Different RNA and protein expression of surface markers in rabbit amniotic fluid-derived mesenchymal stem cells. *Biotechnol Prog.* **2017**, *33*, 1601–1613. <https://doi.org/10.1002/btpr.2519> 325  
326  
327

24. Wu, C.C.; Wang, F.; Rong, S.; Ren, J.; Wan, J.S.; Shi, L.X.; Wu, Z.; Liu, T.; Li, Q. Enhancement of osteogenesis of rabbit bone marrow derived mesenchymal stem cells by transfection of human BMP-2 and EGFP recombinant adenovirus via Wnt signaling pathway. *Exp Ther Med.* **2018**, *16*, 4030–4036. <https://doi.org/10.3892/etm.2018.6735> 328  
329  
330

25. Bakhtina, A.; Tohfafarosh, M.; Lichtler, A.; Arinze, T.L. Characterization and differentiation potential of rabbit mesenchymal stem cells for translational regenerative medicine. *In Vitro Cell Dev Biol Anim.* **2014**, *50*, 251–260. <https://doi.org/10.1007/s11626-013-9702-5> 331  
332  
333

26. Lee, T.H.; Huang, Y.H.; Chang, N.K.; Lin, W.C.; Chien, P.W.; Su, T.M.; Hsieh, D.J.; Lee, T.C. Characterization and spinal fusion effect of rabbit mesenchymal stem cells. *BMC Res Notes.* **2013**, *6*, 528. <https://doi.org/10.1186/1756-0500-6-528> 334  
335

27. Dennis, J.E.; Haynesworth, S.E.; Young, R.G.; Caplan, A.I. Osteogenesis in marrow-derived mesenchymal cell porous ceramic composites transplanted subcutaneously: effect of fibronectin and laminin on cell retention and rate of osteogenic expression. *Cell Transplant.* **1992**, *1*, 23–32. <https://doi.org/10.1177/0963689797200100106> 336  
337  
338

28. Calle, A.; Barrajón-Masa, C.; Gómez-Fidalgo, E.; Martín-Lluch, M.; Cruz-Vigo, P.; Sánchez-Sánchez, R.; Ramírez, M.Á. Iberian pig mesenchymal stem/stromal cells from dermal skin, abdominal and subcutaneous adipose tissues, and peripheral blood: in vitro characterization and migratory properties in inflammation. *Stem Cell Res Ther.* **2018**, *9*, 178. <https://doi.org/10.1186/s13287-018-0933-y> 339  
340

29. Calle, A.; López-Martín, S.; Monguió-Tortajada, M.; Borràs, F.E.; Yáñez-Mó, M.; Ramírez, M.Á. Bovine endometrial MSC: mesenchymal to epithelial transition during luteolysis and tropism to implantation niche for immunomodulation. *Stem Cell Res Ther.* **2019**, *10*, 239. <https://doi.org/10.1186/s13287-018-1129-1> 341  
342  
343  
344

30. Calle, A.; Gutiérrez-Reinoso, M.Á.; Re, M.; Blanco, J.; De la Fuente, J.; Monguió-Tortajada, M.; Borràs, F.E.; Yáñez-Mó, M.; Ramírez, M.Á. Bovine peripheral blood MSCs chemotax towards inflammation and embryo implantation stimuli. *J Cell Physiol.* **2021**, *236*, 1054–1067. <https://doi.org/10.1002/jcp.29915> 345  
346  
347

31. Zomer, H.D.; Roballo, K.C.; Lessa, T.B.; Bressan, F.F.; Gonçalves, N.N.; Meirelles, F.V.; Trentin, A.G.; Ambrósio, C.E. Distinct features of rabbit and human adipose-derived mesenchymal stem cells: implications for biotechnology and translational research. *Stem Cells Cloning.* **2018**, *11*, 43–54. <https://doi.org/10.2147/SCCA.S175749> 348  
349  
350

32. Lin, C.; Shen, M.; Chen, W.; Li, X.; Luo, D.; Cai, J.; Yang, Y. Isolation and purification of rabbit mesenchymal stem cells using an optimized protocol. *In Vitro Cell Dev Biol Anim.* **2015**, *51*, 1102–1108. <https://doi.org/10.1007/s11626-015-9933-8> 351  
352

33. Lee, T.C.; Lee, T.H.; Huang, Y.H.; Chang, N.K.; Lin, Y.J.; Chien, P.W.; Yang, W.H.; Lin, M.H. Comparison of surface markers between human and rabbit mesenchymal stem cells. *PLoS One.* **2014**, *9*, e111390. <https://doi.org/10.1371/journal.pone.0111390> 353  
354

34. Ferrer-Lorente, R.; Bejar, M.T.; Badimon, L. Notch signaling pathway activation in normal and hyperglycemic rats differs in the stem cells of visceral and subcutaneous adipose tissue. *Stem Cells Dev.* **2014**, *23*, 3034–3048. <https://doi.org/10.1089/scd.2014.0070> 355  
356

35. Tchekkona, T. et al. Fat depot-specific characteristics are retained in strains derived from single human preadipocytes. *Diabetes.* **2006**, *55*, 2571–2578. <https://doi.org/10.2337/db06-0540> 357  
358

36. Tran, T.T.; Kahn, C.R. Transplantation of adipose tissue and stem cells: role in metabolism and disease. *Nat Rev Endocrinol.* **2010**, *6*, 195–213. <https://doi.org/10.1038/nrendo.2010.20> 359  
360

37. Macotela, Y.; Emanuelli, B.; Mori, M.A.; Gesta, S.; Schulz, T.J.; Tseng, Y.H., Kahn, C.R. Intrinsic differences in adipocyte precursor cells from different white fat depots. *Diabetes*. **2012**, *61*, 1691-1699. <https://doi.org/10.2337/db11-1753> 361  
362

38. Gesta, S.; Blüher, M.; Yamamoto, Y.; Norris, A.W.; Berndt, J.; Kralisch, S.; Boucher, J.; Lewis, C., Kahn, C.R. Evidence for a role of developmental genes in the origin of obesity and body fat distribution. *Proc Natl Acad Sci U S A.* **2006**, *103*, 6676-6681. <https://doi.org/10.1073/pnas.0601752103> 363  
364  
365

39. Tchkonia, T. et al. Identification of depot-specific human fat cell progenitors through distinct expression profiles and developmental gene patterns. *Am J Physiol Endocrinol Metab.* **2007**, *292*, E298-307. <https://doi.org/10.1152/ajpendo.00202.2006> 366  
367

40. Fischer, B.; Chavatte-Palmer, P.; Viebahn, C.; Navarrete Santos, A., Duranthon, V. Rabbit as a reproductive model for human health. *Reproduction*. **2012**, *144*, 1-10. <https://doi.org/10.1530/REP-12-0091> 368  
369

41. Jazedje, T.; Perin, P.M.; Czeresnia, C.E.; Maluf, M.; Halpern, S.; Secco, M.; Bueno, D.F.; Vieira, N.M.; Zucconi, E., Zatz, M. Human fallopian tube: a new source of multipotent adult mesenchymal stem cells discarded in surgical procedures. *J Transl Med.* **2009**, *7*, 46. <https://doi.org/10.1186/1479-5876-7-46> 370  
371  
372

42. Wang, C.; Liu, Y.; Chang, C.; Wu, S.; Gao, J.; Zhang, Y.; Chen, Y.; Zhong, F., Deng, G. Human fallopian tube proteome shows high coverage of mesenchymal stem cells associated proteins. *Biosci Rep.* **2016**, *36*, e00297. <https://doi.org/10.1042/BSR20150220> 373  
374

43. Rahimzadeh, A.; Mirakabad, F.S.; Movassaghpoor, A.; Shamsasenjan, K.; Kariminekoo, S.; Talebi, M.; Shekari, A.; Zeighamian, V.; Ghalhar, M.G., Akbarzadeh, A. Biotechnological and biomedical applications of mesenchymal stem cells as a therapeutic system. *Artif Cells Nanomed Biotechnol.* **2016**, *44*, 559-570. <https://doi.org/10.3109/21691401.2014.968823> 375  
376  
377

44. Wang, J.; Zhao, Y.; Wu, X.; Yin, S.; Chuai, Y., Wang, A. The utility of human fallopian tube mucosa as a novel source of multipotent stem cells for the treatment of autologous reproductive tract injury. *Stem Cell Res Ther.* **2015**, *6*, 98. <https://doi.org/10.1186/s13287-015-0094-1> 378  
379  
380

45. Jazedje, T. et al. Human fallopian tube mesenchymal stromal cells enhance bone regeneration in a xenotransplanted model. *Stem Cell Rev Rep.* **2012**, *8*, 355-362. <https://doi.org/10.1007/s12015-011-9297-8> 381  
382

46. Shackleton, M.; Vaillant, F.; Simpson, K.J.; Stingl, J.; Smyth, G.K.; Asselin-Labat, M.L.; Wu, L.; Lindeman, G.J., Visvader, J.E. Generation of a functional mammary gland from a single stem cell. *Nature*. **2006**, *439*, 84-88. <https://doi.org/10.1038/nature04372> 383  
384

47. Dalerba, P. et al. Phenotypic characterization of human colorectal cancer stem cells. *Proc Natl Acad Sci U S A.* **2007**, *104*, 10158-10163. <https://doi.org/10.1073/pnas.0703478104> 385  
386

48. Li, C.; Heidt, D.G.; Dalerba, P.; Burant, C.F.; Zhang, L.; Adsay, V.; Wicha, M.; Clarke, M.F., Simeone, D.M. Identification of pancreatic cancer stem cells. *Cancer Res.* **2007**, *67*, 1030-1037. <https://doi.org/10.1158/0008-5472.CAN-06-2030> 387  
388

49. Dawson, C.A., Visvader, J.E. The Cellular Organization of the Mammary Gland: Insights From Microscopy. *J Mammary Gland Biol Neoplasia.* **2021**, *26*, 71-85. <https://doi.org/10.1007/s10911-021-09483-6> 389  
390

50. Song, J.; Ding, W.; Liu, Y.; Lin, L.; Jia, M.; Liu, S., Xue, K. The mesenchymal property of mouse mammary anlagen repopulating cell population is associated with its stemness. *Gene Expr Patterns.* **2020**, *38*, 119151. <https://doi.org/10.1016/j.gep.2020.119151> 391  
392

51. Joshi, P.A.; Waterhouse, P.D.; Kasaian, K.; Fang, H.; Gulyaeva, O.; Sul, H.S.; Boutros, P.C., Khokha, R. PDGFR $\alpha^+$  stromal adipocyte progenitors transition into epithelial cells during lobulo-alveogenesis in the murine mammary gland. *Nat Commun.* **2019**, *10*, 1760. <https://doi.org/10.1038/s41467-019-09748-z> 393  
394  
395

52. Guest, I.; Ilic, Z., Ma, J. Preparation of epithelial and mesenchymal stem cells from murine mammary gland. *Curr Protoc Toxicol.* **2011**, Chapter 22, Unit22.3. <https://doi.org/10.1002/0471140856.tx2203s50> 396  
397  
398